Skip to main content

Table 5 Asthma-related resources consumption

From: Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study)

Variables

Previous year (N = 27)

After treatment initiation (N = 19)

Asthma-related non-scheduled visits

  

 Primary care

  

  Mean (SD)

3.7 (3.9)

1 (0)

  Number, n (%)

  

   0

7 (25.9)

16 (84.2)

   ≥ 1

15 (55.6)a

2 (10.5)b

  Annual rate per patient-year

2.50

0.22

  Difference

2.28

  CI 95%

1.55–3.01

  p-value*

 < 0.001

 Specialists

  

  Mean (SD)

3.8 (3.3)

1.6 (0.9)

  Number, n (%)

  

   0

10 (37)

14 (73.7)

   ≥ 1

16 (59.3)c

5 (26.3)

  Annual rate per patient-year

2.31

0.83

  Difference

1.47

  CI 95%

0.65–2.30

  p-value*

0.004

Asthma-related hospital admissions

  

 Mean (SD)

2 (1.4)

1 (0)

 Number, n (%)

  

  0

22 (81.5)

17 (89.5)

  ≥ 1

5 (18.5)

2 (10.5)

 Annual rate per patient-year

0.37

0.21

 Difference

0.16

 CI 95%

− 0.21 to 0.53

 p-value*

0.707

Asthma-related ED visits

  

 Mean (SD)

3.8 (4.4)

1 (0)

 Number, n (%)

  

  0

15 (55.6)

14 (73.7)

  ≥ 1

12 (44.4)

5 (26.3)

 Annual rate per patient-year

1.70

0.52

 Difference

1.18

 CI 95%

0.51–1.85

 p-value*

0.007

  1. CI confidence interval, ED emergency department, SD standard deviation
  2. *Fisher’s exact test
  3. aData unknown in 5 cases (18.5%)
  4. bData unknown in 1 case (5.3%)
  5. cData unknown in 1 case (3.7%)